ONSURA
DEAD

Serial Number

87641241

Owner

Teva Pharmaceuticals USA, Inc.

Attorney

Laurence Rickles

Filing Date

Oct 11, 2017

Add to watchlist:

No watchlists yet
View on USPTO

ONSURA Trademark

Serial Number: 87641241

ONSURA is a trademark filed by Teva Pharmaceuticals USA, Inc. on October 11, 2017. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

Teva Pharmaceuticals USA, Inc. (587 trademarks)

650 Cathill Road
Sellersville, PA 18960

Entity Type: 03

Trademark Details

Filing Date

October 11, 2017

Registration Date

Not Registered

Published for Opposition

December 25, 2018

Goods & Services

Pharmaceutical preparations for the prevention and treatment of alzheimer's disease; pharmaceutical preparations for the prevention and treatment of depression; pharmaceutical preparations for the prevention and treatment of psychological disorders; pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; pharmaceutical preparations for the prevention and treatment of osteoporosis; pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; pharmaceutical preparations for the prevention and treatment of sexual dysfunction; pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; pharmaceutical preparations for the prevention and treatment of aids-related disorders; pharmaceutical preparations that support, encourage and promote bone strength; pharmaceutical preparations that support, encourage and promote bone health; pharmaceutical preparations used in the treatment of bone disorders and bone diseases; pharmaceutical preparations, namely, injectable contraceptives; pharmaceutical preparations, namely, contraceptive preparations; pharmaceutical preparations, namely, fertility enhancement preparations; pharmaceutical preparations, namely, hormone replacement therapy preparations; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations, namely, pharmaceutical agents affecting the central nervous system; pharmaceutical preparations, namely, pharmaceutical agents affecting circulatory systems; pharmaceutical preparations, namely, pharmaceutical agents affecting sensory organs; pharmaceutical preparations, namely, pharmaceutical agents affecting urogenital organs; pharmaceutical preparations, namely, pharmaceutical agents affecting peripheral nervous system

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Mar 28, 2022 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Mar 28, 2022 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 10, 2021 EXRA
SOU EXTENSION 5 GRANTED
Aug 9, 2021 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Aug 9, 2021 AITU
SOU EXTENSION 5 FILED
Aug 4, 2021 EXT5
SOU TEAS EXTENSION RECEIVED
Aug 4, 2021 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 13, 2021 EXRA
SOU EXTENSION 4 GRANTED
Feb 11, 2021 EX4G
SOU EXTENSION 4 FILED
Feb 11, 2021 EXT4
SOU TEAS EXTENSION RECEIVED
Feb 11, 2021 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 15, 2020 EXRA
SOU EXTENSION 3 GRANTED
Aug 13, 2020 EX3G
SOU EXTENSION 3 FILED
Aug 13, 2020 EXT3
SOU TEAS EXTENSION RECEIVED
Aug 13, 2020 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 29, 2020 EXRA
SOU EXTENSION 2 GRANTED
Feb 19, 2020 EX2G
SOU EXTENSION 2 FILED
Feb 19, 2020 EXT2
SOU TEAS EXTENSION RECEIVED
Feb 19, 2020 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 16, 2019 EXRA
SOU EXTENSION 1 GRANTED
Aug 14, 2019 EX1G
SOU EXTENSION 1 FILED
Aug 14, 2019 EXT1
SOU TEAS EXTENSION RECEIVED
Aug 14, 2019 EEXT
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Aug 13, 2019 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Aug 13, 2019 REAP
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 19, 2019 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 25, 2018 NPUB
PUBLISHED FOR OPPOSITION
Dec 25, 2018 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 5, 2018 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 16, 2018 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 13, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 13, 2018 CRFA
ASSIGNED TO LIE
Nov 6, 2018 ALIE
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Oct 26, 2018 ERSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Aug 7, 2018 GNS3
LETTER OF SUSPENSION E-MAILED
Aug 7, 2018 GNSL
SUSPENSION LETTER WRITTEN
Aug 7, 2018 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 12, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 11, 2018 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 11, 2018 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 16, 2018 GNRN
NON-FINAL ACTION E-MAILED
Jan 16, 2018 GNRT
NON-FINAL ACTION WRITTEN
Jan 16, 2018 CNRT
ASSIGNED TO EXAMINER
Jan 10, 2018 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 18, 2017 NWOS
NEW APPLICATION ENTERED
Oct 14, 2017 NWAP